On the other hand, evidences mainly collected from animal models, have indicated the role of GLP-1 in increasing beta cell proliferation and differentiation and in decreasing the rate of beta cell apoptosis. In the skeletal muscle of these two models, exenatide treatment activated the AMP-activated protein kinase (AMPK) signaling pathway, stimulated lipid oxidation enzymes, and upregulated the insulin signaling pathway. It's primarily prescribed to manage type 2 diabetes by improving insulin sensitivity, controlling blood sugar levels, and aiding weight loss through daily appetite support formula suppression and delayed gastric emptying. People using these medicines can lose more weight than with diet and exercise alone - a loss of between 5% and 21% of their body weight can be expected depending on which medicine is taken and how long it is used. Pharmacologic engagement of the GLP-1R is a proven strategy for treating hyperglycemia in diabetes and reducing body weight. People with low estrogen levels often experience central obesity, which is an accumulation of weight around the trunk of the body. Soon after the drugs came onto the market, they were found to be quite useful to lose weight, which led the companies to develop analogous forms of the diabetes drugs that were designed and approved for weight loss.